338 related articles for article (PubMed ID: 9097765)
1. The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma.
Prünte C; Flammer J
Ophthalmology; 1995 Sep; 102(9):1291-7. PubMed ID: 9097765
[TBL] [Abstract][Full Text] [Related]
2. Topical SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, lowers intraocular pressure in conscious rabbits.
Prünte C; Nuttli I; Markstein R
Jpn J Ophthalmol; 1996; 40(2):167-73. PubMed ID: 8876383
[TBL] [Abstract][Full Text] [Related]
3. Effects of dopamine D-1 and D-2 receptors on intraocular pressure in conscious rabbits.
Prünte C; Nuttli I; Markstein R; Kohler C
J Neural Transm (Vienna); 1997; 104(2-3):111-23. PubMed ID: 9203075
[TBL] [Abstract][Full Text] [Related]
4. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
5. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
DuBiner HB; Hubatsch DA
BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
[TBL] [Abstract][Full Text] [Related]
6. Dopamine, dopaminergic drugs and ocular hypertension.
Virno M; Gazzaniga A; Taverniti L; Pecori Giraldi J; De Gregorio F
Int Ophthalmol; 1992 Sep; 16(4-5):349-53. PubMed ID: 1358853
[TBL] [Abstract][Full Text] [Related]
7. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
8. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study.
Berlin MS; Rowe-Rendleman C; Ahmed I; Ross DT; Fujii A; Ouchi T; Quach C; Wood A; Ward CL
Br J Ophthalmol; 2016 Jun; 100(6):843-7. PubMed ID: 26453641
[TBL] [Abstract][Full Text] [Related]
9. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
10. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
11. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
[TBL] [Abstract][Full Text] [Related]
12. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
[TBL] [Abstract][Full Text] [Related]
14. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
King AJ; Rotchford AP
JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831
[TBL] [Abstract][Full Text] [Related]
15. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
Watson P; Stjernschantz J
Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Stacy R; Huttner K; Watts J; Peace J; Wirta D; Walters T; Sall K; Seaman J; Ni X; Prasanna G; Mogi M; Adams C; Yan JH; Wald M; He Y; Newton R; Kolega R; Grosskreutz C
Am J Ophthalmol; 2018 Aug; 192():113-123. PubMed ID: 29802818
[TBL] [Abstract][Full Text] [Related]
17. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
18. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension.
Narayanaswamy A; Neog A; Baskaran M; George R; Lingam V; Desai C; Rajadhyaksha V
Indian J Ophthalmol; 2007; 55(2):127-31. PubMed ID: 17322603
[TBL] [Abstract][Full Text] [Related]
19. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
[TBL] [Abstract][Full Text] [Related]
20. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
